# Novo Nordisk
Latest news and articles about Novo Nordisk
Total: 3 articles found
Wall Street Opens Soft as GLP‑1 Makers Rally and a Generic Challenger Collapses
U.S. markets opened slightly lower as gains in GLP‑1 weight‑loss drug makers were offset by weakness in memory stocks. Novo Nordisk and Eli Lilly rose on continued enthusiasm for semaglutide‑class therapies, while Hims & Hers plunged after facing litigation over a generic version. Micron fell amid renewed pressure on cyclical tech names.
Guidance Shock Sends AMD Sliding as US Stocks Open Mixed
US equity markets opened mixed as investor focus on corporate guidance produced sharp moves in individual stocks. AMD plunged after lowering its Q1 revenue outlook, while Super Micro surged on an earnings beat and Novo Nordisk fell after trimming guidance, highlighting a guidance-driven, sector‑specific market landscape.
Slimmer Passengers, Fatter Margins: How GLP‑1 Weight‑loss Drugs Could Trim Airline Fuel Bills
Jefferies forecasts that GLP‑1 weight‑loss drugs could cut U.S. major airlines’ fuel bills by up to $580 million annually as lighter passengers reduce aircraft payload. While direct fuel savings are small, fleet‑wide weight reductions can meaningfully boost margins, raising corporate and ethical questions about relying on medical trends for cost savings.